{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:50:46Z","timestamp":1784631046936,"version":"3.55.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000341","name":"Arthritis Research UK","doi-asserted-by":"publisher","award":["20747"],"award-info":[{"award-number":["20747"]}],"id":[{"id":"10.13039\/501100000341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health Research Manchester Biomedical Research Centre"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1093\/rheumatology\/key262","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T11:51:22Z","timestamp":1533556282000},"page":"94-102","source":"Crossref","is-referenced-by-count":25,"title":["Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra"],"prefix":"10.1093","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-1575","authenticated-orcid":false,"given":"Lianne","family":"Kearsley-Fleet","sequence":"first","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-9911","authenticated-orcid":false,"given":"Michael W","family":"Beresford","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine (Child Health), University of Liverpool, UK"},{"name":"Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Davies","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik","family":"De Cock","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Baildam","sequence":"additional","affiliation":[{"name":"Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E","family":"Foster","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Paediatric Rheumatology, Great North Children\u2019s Hospital, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taunton R","family":"Southwood","sequence":"additional","affiliation":[{"name":"Institute of Child Health, University of Birmingham and Birmingham Children\u2019s Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Thomson","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Genetics and Genomics, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"},{"name":"National Institute of Health Research Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK"},{"name":"National Institute of Health Research Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"key\n\t\t\t\t2018121406543312200_key262-B1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","article-title":"Prevalence and incidence of juvenile idiopathic arthritis: a systematic review","volume":"81","author":"Thierry","year":"2014","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B3","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199592630.001.0001","volume-title":"Paediatric rheumatology","author":"Foster","year":"2012","edition":"1st edn"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","article-title":"Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications","volume":"76","author":"Ombrello","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","article-title":"The pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis","volume":"10","author":"Lin","year":"2011","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/AHMT.S109495","article-title":"Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition","volume":"8","author":"Grevich","year":"2017","journal-title":"Adolesc Health Med Ther"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B9","author":"NICE","year":"2002"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B10","author":"NHS England","year":"2015"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B11","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/kev429","article-title":"Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers","volume":"55","author":"Kearsley-Fleet","year":"2016","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B12","author":"EMA","year":"2011"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B13","author":"NICE. TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis","year":"2011"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00296-016-3595-z","article-title":"Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis","volume":"37","author":"Pacharapakornpong","year":"2017","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B17","doi-asserted-by":"crossref","first-page":"e000036","DOI":"10.1136\/rmdopen-2014-000036","article-title":"Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent","volume":"1","author":"Woerner","year":"2015","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B20","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B21","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3899\/jrheum.141567","article-title":"Anakinra in systemic juvenile idiopathic arthritis: a single-center experience","volume":"42","author":"Pardeo","year":"2015","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B23","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B25","first-page":"1120","article-title":"Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis","volume":"59","author":"Magni-Manzoni","year":"2008","journal-title":"Rheum"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B26","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B29","volume-title":"Stata statistical software: release 13. College Station","author":"StataCorp","year":"2013"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheuma"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B31","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","article-title":"Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis","volume":"50","author":"Papsdorf","year":"2011","journal-title":"Rheumatology(Oxford)"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B33","doi-asserted-by":"crossref","first-page":"SR35","DOI":"10.12659\/MSM.882109","article-title":"Etanercept treatment in juvenile idiopathic arthritis: the Polish registry","volume":"17","author":"Zuber","year":"2011","journal-title":"Med Sci Monit"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3899\/jrheum.120842","article-title":"Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept","volume":"40","author":"Solari","year":"2013","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/rheumatology\/ket490","article-title":"German BIKER Registry Collaborative Study Group. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis","volume":"53","author":"Geikowski","year":"2014","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2018121406543312200_key262-B36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kev434","article-title":"Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"55","author":"Kearsley-Fleet","year":"2016","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/1\/94\/27145671\/key262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T23:26:17Z","timestamp":1720481177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/1\/94\/5077391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,8,21]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key262","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,8,21]]}}}